These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16491526)

  • 1. Drug-name game.
    Consum Rep; 2006 Jan; 71(1):9. PubMed ID: 16491526
    [No Abstract]   [Full Text] [Related]  

  • 2. [Generic name or brand name?].
    Ekanger K
    Tidsskr Nor Laegeforen; 2006 Apr; 126(8):1081; author reply 1082. PubMed ID: 16619073
    [No Abstract]   [Full Text] [Related]  

  • 3. Haloperidol for postoperative nausea and vomiting: are we reinventing the wheel?
    Habib AS; Gan TJ
    Anesth Analg; 2008 May; 106(5):1343-5. PubMed ID: 18420842
    [No Abstract]   [Full Text] [Related]  

  • 4. [Generic preparations and name confusion].
    Nielsen J
    Ugeskr Laeger; 2004 May; 166(23):2273. PubMed ID: 15487531
    [No Abstract]   [Full Text] [Related]  

  • 5. Epo, by any other name.
    Nature; 2007 Sep; 449(7160):259. PubMed ID: 17882170
    [No Abstract]   [Full Text] [Related]  

  • 6. The 'little, round, white pill' problem.
    Benfield WR
    Am Pharm; 1992 Jun; NS32(6):44-7. PubMed ID: 1615839
    [No Abstract]   [Full Text] [Related]  

  • 7. Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.
    Kong Y
    Health Econ; 2009 May; 18(5):591-606. PubMed ID: 18816580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dispensing pattern of generic and brand-name drugs in children.
    Chen AY; Wu S
    Ambul Pediatr; 2008; 8(3):189-94. PubMed ID: 18501866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Get informed consent for risky drugs.
    Johnson LJ
    Med Econ; 2007 Nov; 84(21):20. PubMed ID: 18074929
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of generic-only drug benefits on seniors' medication use and financial burden.
    Tseng CW; Brook RH; Keeler E; Steers WN; Waitzfelder BE; Mangione CM
    Am J Manag Care; 2006 Sep; 12(9):525-32. PubMed ID: 16961441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. US court rules that patients harmed by generic drugs cannot claim damages.
    Dyer C
    BMJ; 2011 Jun; 342():d4079. PubMed ID: 21715458
    [No Abstract]   [Full Text] [Related]  

  • 12. Sword or shield? An overview and competitive analysis of the marketing of "authorized generics".
    Zain S
    Food Drug Law J; 2007; 62(4):739-77. PubMed ID: 18557229
    [No Abstract]   [Full Text] [Related]  

  • 13. Two formulations.
    Reg Anesth; 1992; 17(2):118. PubMed ID: 1581260
    [No Abstract]   [Full Text] [Related]  

  • 14. Authorized generic drugs, price competition, and consumers' welfare.
    Berndt ER; Mortimer R; Bhattacharjya A; Parece A; Tuttle E
    Health Aff (Millwood); 2007; 26(3):790-9. PubMed ID: 17485758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Same drug, different dosing: differences in dosing for drugs approved in the United States, Europe, and Japan.
    Malinowski HJ; Westelinck A; Sato J; Ong T
    J Clin Pharmacol; 2008 Aug; 48(8):900-8. PubMed ID: 18524997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Off-label use of drugs in pediatrics].
    Fanconi S; Barazzone Argiroffo C
    Rev Med Suisse; 2009 Feb; 5(191):387. PubMed ID: 19331093
    [No Abstract]   [Full Text] [Related]  

  • 18. Physician use of brand versus generic drug names in 1993-1994 and 2003-2004.
    Kwo EC; Kamat P; Steinman MA
    Ann Pharmacother; 2009 Mar; 43(3):459-68. PubMed ID: 19261956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reference pricing of pharmaceuticals.
    Brekke KR; Königbauer I; Straume OR
    J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.